Innate Pharma (IPHYF) Total Assets by Year
Innate Pharma closed fiscal year 2025 with $73.6M in total assets, $99.1M in total liabilities and -$25.5M in shareholder equity. Total assets fell 36.0% from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters Innate Pharma has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IPHYF Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $73.6M-36.0% | $115.0M-40.7% | $193.8M-9.1% | $213.2M-29.6% | $302.8M-19.5% | $376.0M-16.6% | $450.6M-12.8% | $516.9M+68.6% | $306.6M |
| Total Liabilities | $99.1M-6.4% | $105.8M-22.4% | $136.4M-12.2% | $155.3M-14.3% | $181.2M-2.2% | $185.2M-10.3% | $206.5M-36.5% | $325.5M+74.0% | $187.0M |
| Total Equity | -$25.5M-378.6% | $9.1M-84.1% | $57.4M-0.9% | $57.9M-52.4% | $121.6M-36.3% | $190.8M-21.8% | $244.1M+27.5% | $191.5M+60.1% | $119.6M |
IPHYF Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'246-K | Q4'2320-F | Q2'236-K | Q4'2220-F | Q2'226-K | Q4'2120-F | Q2'216-K | Q4'2020-F | Q4'1920-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $73.6M-36.0% | $109.4M-32.6% | $115.0M-40.7% | $162.3M-25.3% | $193.8M-9.1% | $217.4M-26.0% | $213.2M-29.6% | $293.6M-6.9% | $302.8M-19.5% | $315.4M | $376.0M-16.6% | $450.6M-12.8% |
| Total Liabilities | $99.1M-6.4% | $103.3M-21.4% | $105.8M-22.4% | $131.4M-14.8% | $136.4M-12.2% | $154.2M-10.3% | $155.3M-14.3% | $171.8M+9.3% | $181.2M-2.2% | $157.2M | $185.2M-10.3% | $206.5M-36.5% |
| Total Equity | -$25.5M-378.6% | $6.1M-80.4% | $9.1M-84.1% | $30.8M-51.2% | $57.4M-0.9% | $63.2M-48.1% | $57.9M-52.4% | $121.8M-23.0% | $121.6M-36.3% | $158.2M | $190.8M-21.8% | $244.1M+27.5% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Innate Pharma financials
Frequently Asked Questions
Innate Pharma closed fiscal year 2025 with $73.6M in total assets, $99.1M in total liabilities and -$25.5M in shareholder equity.
Innate Pharma (IPHYF) total assets fell by 36.0% year over year, from $115.0M to $73.6M in fiscal year 2025.
Across the 9 fiscal years this page covers, Innate Pharma (IPHYF) total assets went from $306.6M in fiscal year 2017 to $73.6M in fiscal year 2025.
Innate Pharma (IPHYF) reported $73.6M in total assets in Q4 2025. This represents a decrease of 36.0% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Innate Pharma (IPHYF) reported on that line in every period on record.